Drug Topics E-News:
Having trouble viewing this e-mail? Click here.
You are subscribed to %%list.name%% as %%emailaddr%%.
Unsubscribe from this list.
Modern Medicine Network
  Drug Topics E-News
 
AUGUST 04 , 2009
IN THIS ISSUE
NCPA fights surety bond
FDA OKs FORTEO use
Ariz. to give vaccines
FDA approves vaccines
  TOP SEARCHES: CE // Diabetes // Vertex

NCPA continues fight against surety bond
The National Community Pharmacists Association (NCPA) is still working to urge Congress to exempt community pharmacies from the Oct. 1 accreditation and surety bond requirements needed to continue providing Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) to Medicare patients. More...

FDA approves new drug indication for Forteo
On July 23, Eli Lilly and Company announced the Food and Drug Administration (FDA) has approved a new use for its osteoporosis drug FORTEO to treat osteoporosis associated with sustained, systemic glucocorticoid therapy in men and women at high risk of fracture. Glucocorticoid therapy is the most common cause of secondary osteoporosis, leading to bone loss and an increased risk for fracture, according to a statement from Eli Lilly. More...

Arizona pharmacists to begin administering vaccines
Arizona has just been added to the states where pharmacists are taking on a few added responsibilities, namely administering immunizations. To find out more about the law that started it all, keep reading. More...

FDA approves vaccines for upcoming flu season
The U.S. Food and Drug Administration has announced that it has approved a vaccine for 2009-2010 seasonal influenza in the United States. The seasonal influenza vaccine will not protect against the 2009 H1N1 influenza virus that resulted in the declaration of a pandemic by the World Health Organization (WHO) on June 11, 2009. More...


Key Topic Updates
Issues & Trends
 
Professional
 
Clinical
 
Technology
 
Regulatory & Law

Key Topic Updates

Survey
Is direct-to-consumer advertising a good idea?
Yes   10%
No   90%

This month we would like to know...

How often do you implement therapeutic substitution?

<20% of prescriptions 21 to 50% of prescriptions 51 to 75% of prescriptions >75% of prescriptions

Click here to vote


Contact Us
Click here to learn more about the Drug Topics editorial team.

Click here to contact the Drug Topics editorial team.

Click here to contact the Drug Topics sales team.

Click here to learn about direct mail, reprints and classifieds in Drug Topics.

Drug Topics Digital Edition
Click here to to view the most recent issue.

Click here to subscribe.


You are subscribed to %%list.name%% as %%emailaddr%%. To unsubscribe from this list click here.

To ensure delivery to your Inbox, please add %%email.list%% to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.